JP7507160B2 - ヒトtrbv9に特異的に結合するモノクローナル抗体 - Google Patents

ヒトtrbv9に特異的に結合するモノクローナル抗体 Download PDF

Info

Publication number
JP7507160B2
JP7507160B2 JP2021537704A JP2021537704A JP7507160B2 JP 7507160 B2 JP7507160 B2 JP 7507160B2 JP 2021537704 A JP2021537704 A JP 2021537704A JP 2021537704 A JP2021537704 A JP 2021537704A JP 7507160 B2 JP7507160 B2 JP 7507160B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
antigen
antibodies
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021537704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515820A5 (cg-RX-API-DMAC7.html
JP2022515820A (ja
Inventor
ブリタノワ,オルガ・ウラジミロフナ
スタロフェロフ,ドミトリー・ボリソビッチ
エフストラテワ,アンナ・バレンチノフナ
ミソリン,アレクセイ・コンスタンチノビッチ
ネマンキン,ティモフェイ・アレクサンドロビッチ
シュチェメレワ,マリーア・アレクサンドロフナ
ウラディミロワ,アンナ・コンスタンティノフナ
アニキナ,アリーナ・ビタレフナ
イワノフ,ロマン・アレクセービッチ
モロゾフ,ドミトリ・バレンチノビッチ
イアコフレフ,パベル・アンドレービッチ
ルキャノフ,セルゲイ・アナトリエビッチ
Original Assignee
ジョイント・ストック・カンパニー “バイオキャド”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2018146029A external-priority patent/RU2711871C3/ru
Application filed by ジョイント・ストック・カンパニー “バイオキャド” filed Critical ジョイント・ストック・カンパニー “バイオキャド”
Publication of JP2022515820A publication Critical patent/JP2022515820A/ja
Publication of JP2022515820A5 publication Critical patent/JP2022515820A5/ja
Application granted granted Critical
Publication of JP7507160B2 publication Critical patent/JP7507160B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021537704A 2018-12-25 2019-12-24 ヒトtrbv9に特異的に結合するモノクローナル抗体 Active JP7507160B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2018146029A RU2711871C3 (ru) 2018-12-25 Моноклональные антитела, которые специфически связываются с участком бета цепи семейства TRBV-9 Т-клеточного рецептора человека, и способы их применения
RU2018146029 2018-12-25
PCT/RU2019/050257 WO2020139171A1 (ru) 2018-12-25 2019-12-24 Моноклональные антитела, специфически связывающиеся с trbv-9 человека

Publications (3)

Publication Number Publication Date
JP2022515820A JP2022515820A (ja) 2022-02-22
JP2022515820A5 JP2022515820A5 (cg-RX-API-DMAC7.html) 2023-01-10
JP7507160B2 true JP7507160B2 (ja) 2024-06-27

Family

ID=69184146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021537704A Active JP7507160B2 (ja) 2018-12-25 2019-12-24 ヒトtrbv9に特異的に結合するモノクローナル抗体

Country Status (26)

Country Link
US (1) US12297269B2 (cg-RX-API-DMAC7.html)
EP (2) EP4721817A2 (cg-RX-API-DMAC7.html)
JP (1) JP7507160B2 (cg-RX-API-DMAC7.html)
KR (1) KR102974826B1 (cg-RX-API-DMAC7.html)
CN (1) CN113692412B (cg-RX-API-DMAC7.html)
AR (1) AR117735A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021012550A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124800A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001704A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021008204A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210353A (cg-RX-API-DMAC7.html)
EA (1) EA202100199A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21046332A (cg-RX-API-DMAC7.html)
IL (1) IL284367A (cg-RX-API-DMAC7.html)
JO (1) JOP20210168B1 (cg-RX-API-DMAC7.html)
MA (1) MA53688B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021007718A (cg-RX-API-DMAC7.html)
MY (1) MY206214A (cg-RX-API-DMAC7.html)
PE (1) PE20211792A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551535A1 (cg-RX-API-DMAC7.html)
RS (1) RS68101B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106974SA (cg-RX-API-DMAC7.html)
SM (1) SMT202600227T1 (cg-RX-API-DMAC7.html)
TW (1) TWI914298B (cg-RX-API-DMAC7.html)
WO (1) WO2020139171A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104356B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
TW202417487A (zh) * 2022-08-18 2024-05-01 俄羅斯聯邦商拜奧卡德聯合股份公司 治療在t細胞受體內帶有trbv9節段的t淋巴細胞所介導的疾病或病症之方法
KR20260085152A (ko) * 2023-10-04 2026-06-08 조인트 스탁 컴퍼니 "바이오케드" 인간 tcr 도메인의 trbv5-1 세그먼트에 결합하는 항체

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012008397A1 (ja) 2010-07-12 2012-01-19 第一三共株式会社 抗epha2抗体及びその用途
WO2014177771A1 (en) 2013-05-02 2014-11-06 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
WO2017137453A1 (en) 2016-02-08 2017-08-17 Polybiocept Ab T-cell receptor sequences for active immunotherapy
WO2017216324A1 (en) 2016-06-17 2017-12-21 Medigene Immunotherapies Gmbh T cell receptors and uses thereof
WO2019132738A1 (ru) 2017-12-25 2019-07-04 Закрытое Акционерное Общество "Биокад" Моноклональные антитела и способы их применения

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5223426A (en) 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
CA2765949C (en) * 2009-06-25 2016-03-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
AU2017356322B2 (en) * 2016-11-14 2023-09-21 Fred Hutchinson Cancer Center High affinity merkel cell polyomavirus T antigen-specific TCRs and uses thereof
JP7162607B2 (ja) * 2017-02-27 2022-10-28 中外製薬株式会社 抗hla-dq2.5/8抗体およびセリアック病の治療のためのその使用
CN107502671B (zh) * 2017-10-12 2020-05-05 中国医学科学院肿瘤医院 利用trbv家族成员预测曲妥珠单抗新辅助治疗乳腺癌患者疗效试剂盒及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012008397A1 (ja) 2010-07-12 2012-01-19 第一三共株式会社 抗epha2抗体及びその用途
WO2014177771A1 (en) 2013-05-02 2014-11-06 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
WO2017137453A1 (en) 2016-02-08 2017-08-17 Polybiocept Ab T-cell receptor sequences for active immunotherapy
WO2017216324A1 (en) 2016-06-17 2017-12-21 Medigene Immunotherapies Gmbh T cell receptors and uses thereof
WO2019132738A1 (ru) 2017-12-25 2019-07-04 Закрытое Акционерное Общество "Биокад" Моноклональные антитела и способы их применения

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BULLETIN OF RSMU,2018年12月05日,Vol.5,pp.71-79
Clinical and Experimental Immunology,2003年,Vol.134,pp.92-97
Immunity,2012年,Vol.37,pp.611-621
J. Immunol.,2015年,Vol.194, No.12,pp.6112-6122

Also Published As

Publication number Publication date
US12297269B2 (en) 2025-05-13
JOP20210168A1 (ar) 2023-01-30
SG11202106974SA (en) 2021-07-29
JP2022515820A (ja) 2022-02-22
MY206214A (en) 2024-12-04
CL2021001704A1 (es) 2022-01-28
KR102974826B1 (ko) 2026-06-09
MA53688A1 (fr) 2022-06-30
CN113692412A (zh) 2021-11-23
TW202033557A (zh) 2020-09-16
RS68101B1 (sr) 2026-06-30
AU2019416787A1 (en) 2021-08-12
EA202100199A1 (ru) 2021-12-02
EP4721817A2 (en) 2026-04-08
SMT202600227T1 (it) 2026-07-16
CO2021008204A2 (es) 2021-08-30
KR20210118843A (ko) 2021-10-01
AR117735A1 (es) 2021-08-25
PH12021551535A1 (en) 2022-02-28
WO2020139171A1 (ru) 2020-07-02
MX2021007718A (es) 2021-08-05
CN113692412B (zh) 2024-08-16
PE20211792A1 (es) 2021-09-09
ECSP21046332A (es) 2021-07-30
JOP20210168B1 (ar) 2025-10-01
ZA202104356B (en) 2022-09-28
RU2711871C1 (ru) 2020-01-23
CR20210353A (es) 2021-12-20
TWI914298B (zh) 2026-02-11
EP3904387A4 (en) 2022-09-07
EP3904387A1 (en) 2021-11-03
BR112021012550A2 (pt) 2021-09-14
US20220056133A1 (en) 2022-02-24
MA53688B1 (fr) 2023-03-31
NZ778430A (en) 2026-01-30
CA3124800A1 (en) 2020-07-02
EP3904387B1 (en) 2026-02-11
IL284367A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
US12514923B2 (en) Methods of inhibiting the T cell receptor by administering a monoclonal antibody that binds TRBV9
US12227572B2 (en) Monoclonal antibodies against the beta chain region of human TRBV9
US12297269B2 (en) Monoclonal antibodies that bind specifically to human TRBV9
EA042982B1 (ru) Моноклональные антитела против участка бета-цепи trbv9 человека
OA20245A (en) Monoclonal antibodies that bind specifically to human TRBV9.
OA20246A (en) Monoclonal antibodies against the beta chain region of human TRBV9.
HK40063875A (en) Monoclonal antibodies against the beta chain region of human trbv9
HK40039968B (en) Monoclonal antibodies and methods for using same
HK40039968A (en) Monoclonal antibodies and methods for using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240617